gc012f
Cell therapyexperimental
Clinical trial activity
22 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
22
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Jan 15, 2020 (NCT04236011)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
- BCMAImmunity, passive
BCMA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07303790 | Early Phase 1 (Phase 1) | Jan 20, 2026 | Huazhong University of Science and Technology |
| NCT07224373 | Phase 1 | Dec 23, 2025 | AstraZeneca |
| NCT07295847 | Phase 1 | Dec 16, 2025 | AstraZeneca |
| NCT07250269 | Phase 1 | Oct 29, 2025 | Gracell Biotechnology Ltd. |
| NCT07086404 | Early Phase 1 (Phase 1) | Sep 15, 2025 | Gracell Biotechnology Ltd., Huazhong University of Science and Technology |
| NCT07072884 | Early Phase 1 (Phase 1) | Aug 18, 2025 | Gracell Biotechnology Ltd., Jiao Tong University |
| NCT07081646 | Phase 1/Phase 2 (Phase 2) | Aug 18, 2025 | Alexion |
| NCT07073547 | Phase 1 | Jul 31, 2025 | AstraZeneca |
| NCT07058298 | Early Phase 1 (Phase 1) | Jul 15, 2025 | Gracell Biotechnology Ltd., Huazhong University of Science and Technology |
| NCT06897930 | Phase 1/Phase 2 (Phase 2) | Apr 21, 2025 | AstraZeneca |
| NCT06759948 | Phase 1 | Feb 15, 2025 | Fudan University, Gracell Biotechnology Ltd. |
| NCT06419166 | Early Phase 1 (Phase 1) | Dec 1, 2024 | Gracell Biotechnology Ltd., Zhejiang University |
| NCT06530849 | Phase 1/Phase 2 (Phase 2) | Aug 22, 2024 | AstraZeneca, Gracell Biotechnology Ltd. |
| NCT06235229 | Phase 1/Phase 2 (Phase 2) | Dec 7, 2023 | Gracell Biotechnology Ltd. |
| NCT05850234 | Phase 1/Phase 2 (Phase 2) | Jul 20, 2023 | Gracell Biotechnology Ltd. |
| NCT05840107 | Early Phase 1 (Phase 1) | May 15, 2023 | Gracell Biotechnology Ltd., Second Military Medical University |
| NCT05846347 | Phase 1 | May 15, 2023 | Gracell Biotechnology Ltd., Zhejiang University |
| NCT05858684 | Early Phase 1 (Phase 1) | May 11, 2023 | Gracell Biotechnology Ltd., Jiao Tong University |
| NCT05412329 | Phase 1 | Jun 13, 2022 | Gracell Biotechnology Ltd., Second Military Medical University |
| NCT04935580 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2021 | Gracell Biotechnology Ltd., Second Military Medical University |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gracell Biotechnology Ltd. | For profit | 16 | 4 | 2 | 2020 |
| AstraZeneca | For profit | 5 | 4 | 2 | 2024 |
| Second Military Medical University | Government | 5 | 5 | 2 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 3 | 3 | 1 | 2025 |
| Jiao Tong University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Alexion | For profit | 1 | 1 | 1 | 2025 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2025 |
8 organizations
Page 1 / 1